A combination of immune stimulants and immunotherapy that transforms tumors into cancer vaccine-producing factories has shown remarkable promise in a phase 1/2 trial, although only in 30% of patients.
Adults with dermatologic conditions such as hidradenitis suppurativa "may be at increased risk for persistent and high-risk HPV infection" and may benefit from HPV vaccination, study authors said.
The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.
Once again, the US Preventive Services Task Force has concluded that there is insufficient evidence on the balance of benefits vs the harms of screening asymptomatic patients for skin cancer.